At Boehringer Ingelheim our purpose is simply to ‘Make More Health’ - for patients, our people and our community. We are a family-owned, independent company and operate in over 50 countries with more than 44,000 employees. For over a century we have practiced excellence, innovation and value in the discovery of medicines and services and have remained committed to operating as an ethical and sustainable company. We are constantly seeking new and better ways to treat diseases in people and animals. Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research programme to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world’s leading cancer centres, Boehringer Ingelheim’s commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumours and haematological cancers. Our current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. Boehringer Ingelheim’s oncology pipeline is evolving and demonstrates the company’s continued commitment to advance the disease area.
View Site Show On Map